You are here

Article Text

Article menu
Download PDFPDF
Letter
Oral sildenafil for the treatment of Raynaud’s phenomenon and digital ulcers secondary to systemic sclerosis
  1. J Gore,
  2. R Silver
  1. Medical University of South Carolina, Division of Rheumatology, Charleston, South Carolina, USA
  1. Correspondence to:
    Dr J Gore
    Medical University of South Carolina, Division of Rheumatology, 96 Jonathon Lucas Street, Suite 912, PO Box 250623, Charleston, SC 29425, USA; gorejmusc.edu

https://doi.org/10.1136/ard.2004.034488

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Raynaud’s phenomenon (RP) with or without digital ulcer formation is a significant cause of morbidity for patients with systemic sclerosis (SSc, scleroderma). Lichtenstein reported oral sildenafil as a treatment of RP for patients with SSc, systemic lupus erythematosus, and idiopathic RP.1 His report included 10 patients from his community office practice given sildenafil, 50 mg once orally at bedtime.

    METHODS AND RESULTS

    We performed a retrospective chart review of 10 patients with SSc seen at a tertiary care referral centre who were offered sildenafil after standard treatments (calcium channel …

    View Full Text